Published Apr 2, 2024
The Bumpy Road To Approving New Alzheimer’s Drugs
Delving into the contentious landscape of Alzheimer's drug approvals, this episode examines scientific advancements, ethical considerations, and FDA controversies, with Jason Karlawish providing insights on the challenges of healthcare system readiness and the potential of anti-amyloid treatments.
Topics covered
Popular Clips
Episode Highlights
Related Episodes
FDA Panel Rejects MDMA Therapy For PTSD
Answers 383 questions
Why Are There So Many Drug Shortages In The U.S.?
Answers 383 questions
A Young Scientist Uplifts The Needs Of Parkinson’s Patients
Answers 383 questions
Alan Alda Reflects On Life With Parkinson’s
Answers 383 questions
The FDA Approved The First CRISPR-Based Therapy. What’s Next?
Answers 383 questions
The Breakthrough Technologies To Watch In 2025
Answers 383 questions
Surgeon General Highlights Link Between Alcohol And Cancer
Answers 383 questions
Former NIH Director Reflects On Public Mistrust In Science
Answers 383 questionsDr. Fauci On A Life Of Medical Research And Public Service
Answers 383 questions
Could Light And Sound Therapy Treat Alzheimer’s?
Answers 383 questions
From Scans To Office Visits: How Will AI Shape Medicine?
Answers 383 questions
A Nobel Prize For Chemistry Work ‘Totally Separate From Biology’
Answers 383 questions
Scientists Are Uncovering A World Of ‘Dark Matter’ Carcinogens
Answers 383 questionsWhy Cancer Death Rates Have Decreased Over The Last 30 Years
Answers 383 questions
